scispace - formally typeset
E

Elin Org

Researcher at University of Tartu

Publications -  64
Citations -  16893

Elin Org is an academic researcher from University of Tartu. The author has contributed to research in topics: Genome-wide association study & Microbiome. The author has an hindex of 34, co-authored 60 publications receiving 13254 citations. Previous affiliations of Elin Org include University of California, Los Angeles & Cleveland Clinic.

Papers
More filters
Journal ArticleDOI

Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk

Georg Ehret, +391 more
- 06 Oct 2011 - 
TL;DR: A genetic risk score based on 29 genome-wide significant variants was associated with hypertension, left ventricular wall thickness, stroke and coronary artery disease, but not kidney disease or kidney function, and these findings suggest potential novel therapeutic pathways for cardiovascular disease prevention.
Journal ArticleDOI

Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk.

TL;DR: Gut microbes, through generation of trimethylamine N-oxide (TMAO), directly contribute to platelet hyperreactivity and enhanced thrombosis potential, revealing a previously unrecognized mechanistic link between specific dietary nutrients, gut microbes, platelet function, and thromBosis risk.
Journal ArticleDOI

Genome-wide association study identifies eight loci associated with blood pressure

Christopher Newton-Cheh, +362 more
- 01 Jun 2009 - 
TL;DR: In this paper, the association between systolic or diastolic blood pressure and common variants in eight regions near the CYP17A1 (P = 7 × 10(-24)), CYP1A2(P = 1 × 10-23), FGF5 (P=1 × 10 -21), SH2B3(P= 3 × 10−18), MTHFR(MTHFR), c10orf107(P), ZNF652(ZNF652), PLCD3 (P,P = 5 × 10 −9),
Journal ArticleDOI

Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis

TL;DR: The present studies suggest that targeting gut microbial production of TMA specifically and non-lethal microbial inhibitors in general may serve as a potential therapeutic approach for the treatment of cardiometabolic diseases.